Related Experiment Videos

Therapeutic potential of thiazolidinediones as anticancer agents

Dipak Panigrahy1, Lucy Q Shen, Mark W Kieran

  • 1Children's Hospital, Research Building, Floor 12, Boston, MA, USA.

Expert Opinion on Investigational Drugs
|December 4, 2003
PubMed

Insights

Thiazolidinediones (TZDs) show anticancer effects by impacting cell cycles, differentiation, and apoptosis. These compounds also inhibit tumor angiogenesis through PPAR-gamma-dependent and -independent pathways.

Area of Science:

  • Pharmacology
  • Oncology
  • Endocrinology

Background:

  • Thiazolidinediones (TZDs) are synthetic ligands activating peroxisome proliferator-activated receptor-gamma (PPAR-gamma).
  • TZDs are established treatments for Type 2 diabetes.
  • Emerging evidence indicates antitumour properties of TZDs in various cancer models.

Purpose of the Study:

  • To investigate the antitumour mechanisms of TZDs.
  • To explore the role of PPAR-gamma-dependent and -independent pathways in TZD-mediated anticancer effects.
  • To assess the potential of TZDs in cancer prevention and adjuvant therapy.

Main Methods:

  • In vitro and in vivo experimental cancer models.
  • Analysis of cell cycle, differentiation, apoptosis, and angiogenesis.
  • Evaluation of PPAR-gamma-dependent and -independent signaling pathways.
  • Assessment of vascular endothelial growth factor (VEGF) production.

Main Results:

  • TZDs demonstrated antitumour activity by modulating cell cycle, inducing differentiation and apoptosis.
  • Inhibition of tumor angiogenesis was observed, involving direct effects on endothelial cells and reduced VEGF production.
  • Mechanisms were mediated through both PPAR-gamma-dependent and -independent pathways, varying with concentration and tumor type.

Conclusions:

  • TZDs possess significant antitumour potential beyond diabetes treatment.
  • Targeting angiogenesis and cellular proliferation pathways contributes to TZD's anticancer effects.
  • TZDs may serve as a valuable therapeutic agent for cancer prevention and as an adjuvant therapy.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Antihypertensive Drugs: Thiazide-Class Diuretics01:15

Antihypertensive Drugs: Thiazide-Class Diuretics

Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...